Key points GLP-1 is a hormone that increases insulin release and prevents the release of too much glucagon, helping manage blood glucose levels in individuals with type 2 diabetes GLP-1 receptor agonists, such as liraglutide and semaglutide, effectively reduce blood glucose levels Semaglutide is more effective than liraglutide at reducing blood sugar levels Tirzepatide is a newer GLP-1 receptor agonist that also mimics the actions of another hormone called GIP, which can also reduce blood sugar levels A randomised controlled trial showed that tirzepatide led to more significant blood sugar reductions than semaglutide across three doses Tirzepatide may be more effective than semaglutide at higher doses, but this needs further investigation Liraglutide and semaglutide are available in the UK and the US, while tirzepatide is only available in the US but is likely to be approved in the UK soon
To address the global health burden of MASLD, intensified by obesity and type 2 diabetes mellitus epidemics, a holistic, multidisciplinary approach is essential
For other metabolic peptide comparisons, see mazdutide vs semaglutide and mazdutide vs tirzepatide
Patients with metabolic complexity like this generally do better in a structured medical weight management setting where those combinations can be monitored carefully
Understanding Mounjaro Dosage: Injected under the skin once a week, with doses ranging from 2.5 mg to 15 mg weekly
Some patients report appetite changes within the first few days of this dose
